Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Research & Development (2016 - 2025)

Perspective Therapeutics' Research & Development history spans 15 years, with the latest figure at $12.9 million for Q4 2024.

  • For Q4 2024, Research & Development rose 81.96% year-over-year to $12.9 million; the TTM value through Dec 2024 reached $41.6 million, up 93.85%, while the annual FY2024 figure was $41.6 million, 95.38% up from the prior year.
  • Research & Development for Q4 2024 was $12.9 million at Perspective Therapeutics, up from $12.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.9 million in Q4 2024 and bottomed at $285000.0 in Q4 2020.
  • The 5-year median for Research & Development is $752000.0 (2022), against an average of $3.8 million.
  • The largest annual shift saw Research & Development fell 5.57% in 2020 before it surged 708.05% in 2023.
  • A 5-year view of Research & Development shows it stood at $285000.0 in 2020, then skyrocketed by 85.61% to $529000.0 in 2021, then soared by 33.84% to $708000.0 in 2022, then skyrocketed by 900.0% to $7.1 million in 2023, then skyrocketed by 81.96% to $12.9 million in 2024.
  • Per Business Quant, the three most recent readings for CATX's Research & Development are $12.9 million (Q4 2024), $12.0 million (Q3 2024), and $9.3 million (Q2 2024).